Stock of the Day

Bristol-Myers Squibb (BMY)

$48.31

+$0.47 (+1.0%)

Market Cap: $98.27B

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases.

The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Bull Case

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

• The current stock price is around $48, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
• Bristol-Myers Squibb has a diverse portfolio of products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future revenue growth.
• The company has shown strong institutional support, with over 76% of its stock owned by institutional investors, indicating confidence in its long-term prospects.
• Recent insider buying activity, including a significant purchase by an executive vice president, suggests that those within the company believe in its future performance.
• With a market capitalization of approximately $98.21 billion, Bristol-Myers Squibb is a major player in the pharmaceutical industry, providing stability and potential for growth.

Bristol-Myers Squibb Bear Case

Investors should be bearish about investing in Bristol-Myers Squibb for these reasons:

• The company has a price-to-earnings ratio of -10.92, which may raise concerns about profitability and financial health.
• Recent trading volatility, with a 12-month high of $63.33 and a low of $39.35, indicates potential instability in the stock price.
• There is a risk associated with the biopharmaceutical industry, including regulatory challenges and competition from other companies developing similar therapies.
• Despite a strong product pipeline, the success of new treatments is uncertain, which could impact future revenue and stock performance.
• Market conditions and economic factors can affect the overall performance of pharmaceutical stocks, including Bristol-Myers Squibb.

Recent News

• Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)? (insidermonkey.com)
• Bristol-Myers Squibb (NYSE:BMY) Collaborates With BioNTech For Antibody Development In Cancer Treatment (uk.finance.yahoo.com)
• Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector? (msn.com)
• Bristol-Myers Squibb’s Strategic Partnership with BioNTech: A Promising Future for BNT327 in Immunology Therapy (tipranks.com)
• 5 All-Star High-Yield Dividend Stocks Every Boomer Should Own (https://247wallst.com)
• Hold Rating on Bristol-Myers Squibb Amid R&D and Acquisition Strategy Concerns (tipranks.com)
• Cancer Moonshot: Bristol-Myers Just Dropped $11 Billion on a Single BioNTech Drug (uk.finance.yahoo.com)
• Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy (msn.com)
• Bristol-Myers Squibb Company and BioNTech SE Partner to Advance Next-Gen Cancer Therapies (insidermonkey.com)
• BioNTech Gains 20% On $11.1 Billion Bristol Deal (uk.finance.yahoo.com)